INJECTION INDEXWeight management, clearly.
The online care edition
October 2026
The plan index · October 2026

NAD+ Injectable Offer: A Focused Review

A separate therapy with its own purpose and evidence questions.

Read this firstSources checked October 7, 2026

NAD+ is not a GLP-1 weight-loss injection. This is an offer review with a different clinical-evidence question.

Advertised offer
$93/mo

CoreAge NAD+ starting figure; confirm quantity and order terms.

Treatment category
NAD+

Distinct from GLP-1 weight-management medicines.

Clinical question
Evidence and monitoring

Ask what supports the intended use and route.

CoreAge Rx publishes a NAD+ injectable offer starting at $93 per month. This is a different therapy from an approved GLP-1 weight management medicine. An advertised injectable route does not establish a proven weight loss or longevity benefit.

Only the verified treatment-specific offer is listed here. We have not invented a five-provider NAD+ ranking from general wellness pages. Discuss the rationale, formulation, clinical eligibility, and monitoring with the prescribing team before considering an order.

The details, visualized

NAD+ offer: price is only one line

A practical decision map; not a clinical score

  1. Advertised offer$93/mo

    CoreAge NAD+ starting figure; confirm quantity and order terms.

  2. Treatment categoryNAD+

    Distinct from GLP-1 weight-management medicines.

  3. Clinical questionEvidence and monitoring

    Ask what supports the intended use and route.

Use the source documents and your selected agreement. A public description does not determine personal treatment eligibility.

View the printable chart imageNAD+ offer: price is only one line. The same values and context are available in the data table above.
Research note 01

Keep the treatment category explicit

The linked CoreAge page advertises NAD+ injections from $93 per month. That figure establishes an advertised offer; it does not establish that NAD+ causes weight loss or reproduces outcomes in semaglutide and tirzepatide trials. The category deserves its own rationale and evidence review.

Ask the clinician what condition or goal is being addressed, what evidence supports this route, and how benefits and harms would be monitored. Confirm the exact preparation and full order terms. A numerical comparison with a GLP-1 price cannot resolve those medical differences.

Before you decide

Questions worth answering

Does the order on this page identify the best treatment for me?

No. It is a publisher-arranged comparison of selected public offers. The chart explains the specific purchase or evidence question; a licensed clinician must assess the actual treatment.

What should I verify for this comparison?

NAD+ is not a GLP-1 weight-loss injection. This is an offer review with a different clinical-evidence question. Ask for the selected written quote and the product-specific clinical explanation before making a purchase.

Evidence behind this page

Sources & chart notes

Checked October 7, 2026. Provider pages establish advertised terms. Labels and trial reports describe specific medicines and study populations. Medical review has not been completed.

Editorial illustration: a telehealth screen, a question card and an unbranded container.
NAD+ Injectable Offer: A Focused Review — keep the product information and the route for asking a question in the same comparison.

Ask for the clinical objective

The clinician should explain what the therapy is being considered for and what evidence supports that decision for your circumstances. Marketing language about energy or aging is not a guarantee of benefit. The clinical checklist provides a framework for the discussion.

Editorial illustration: an unbranded container, information sheet and magnifying glass.
Ask for the clinical objective — keep the exact product identity and its complete label together.

Confirm the actual prescription and bill

Identify ingredients, amount supplied, pharmacy, and written directions. Confirm the starting offer and renewal for this therapy; a GLP-1 price is not the NAD+ price. Read the provider review for the broader service and refund policy, while confirming treatment-specific details separately.

Explore the review directory and full cost table to compare the details of another offer.

Research record

Documents used

Source register refreshed October 7, 2026. Advertising describes an offer; it is not independent verification of treatment outcomes.

  1. CoreAge Rx: NAD+ injectable offer ↗
  2. FDA: Concerns about unapproved GLP-1 drugs ↗
  3. NIDDK: Prescription medicines for weight management ↗
  4. Wegovy: Official product information ↗
  5. Zepbound: Official product information ↗